Table of Contents
Chemotherapy Research and Practice
Volume 2012 (2012), Article ID 761518, 13 pages
http://dx.doi.org/10.1155/2012/761518
Review Article

The Use of Epidermal Growth Factor Receptor Monoclonal Antibodies in Squamous Cell Carcinoma of the Head and Neck

Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford University, Stanford, CA 94305, USA

Received 9 April 2012; Accepted 3 September 2012

Academic Editor: Missak Haigentz

Copyright © 2012 Jeffery S. Russell and A. Dimitrios Colevas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. ACS, Cancer Facts and Figures 2012, American Cancer Society, Atlanta, Ga, USA, 2012.
  2. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. B. E. Brockstein, “Management of recurrent head and neck cancer: recent progress and future directions,” Drugs, vol. 71, no. 12, pp. 1551–1559, 2011. View at Google Scholar
  4. R. J. Koness, A. Glicksman, L. Liu et al., “Recurrence patterns with concurrent platinum-based chemotherapy and accelerated hyperfractionated radiotherapy in stage III and IV head and neck cancer patients,” American Journal of Surgery, vol. 174, no. 5, pp. 532–535, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Brockstein, D. J. Haraf, A. W. Rademaker et al., “Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience,” Annals of Oncology, vol. 15, no. 8, pp. 1179–1186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. O. Dassonville, J. L. Formento, M. Francoual et al., “Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer,” Journal of Clinical Oncology, vol. 11, no. 10, pp. 1873–1878, 1993. View at Google Scholar · View at Scopus
  7. K. K. Ang, B. A. Berkey, X. Tu et al., “Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma,” Cancer Research, vol. 62, no. 24, pp. 7350–7356, 2002. View at Google Scholar · View at Scopus
  8. C. H. Chung, J. S. Parker, G. Karaca et al., “Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression,” Cancer Cell, vol. 5, no. 5, pp. 489–500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. S. M. Bentzen, B. M. Atasoy, F. M. Daley et al., “Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5560–5567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. H. Chung, K. Ely, L. McGavran et al., “Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4170–4176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Licitra, R. Mesia, F. Rivera et al., “Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study,” Annals of Oncology, vol. 22, no. 5, pp. 1078–1087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Mendelsohn and J. Baselga, “The EGF receptor family as targets for cancer therapy,” Oncogene, vol. 19, no. 56, pp. 6550–6565, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. C. L. Arteaga, “The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia,” Journal of Clinical Oncology, vol. 19, supplement 18, pp. 32S–40S, 2001. View at Google Scholar · View at Scopus
  14. F. Ciardiello and G. Tortora, “A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor,” Clinical Cancer Research, vol. 7, no. 10, pp. 2958–2970, 2001. View at Google Scholar · View at Scopus
  15. J. A. McCubrey, L. S. Steelman, W. H. Chappell et al., “Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance,” Biochimica et Biophysica Acta, vol. 1773, no. 8, pp. 1263–1284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. J. Roberts and C. J. Der, “Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer,” Oncogene, vol. 26, no. 22, pp. 3291–3310, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. B. H. Jiang and L. Z. Liu, “PI3K/PTEN signaling in tumorigenesis and angiogenesis,” Biochimica et Biophysica Acta, vol. 1784, no. 1, pp. 150–158, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” The New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival,” The Lancet Oncology, vol. 11, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. D. G. Pfister, Y. B. Su, D. H. Kraus et al., “Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm,” Journal of Clinical Oncology, vol. 24, no. 7, pp. 1072–1078, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. C. J. Langer, J. W. Lee, U. A. Patel et al., “Preliminary analysis of ECOG, 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN),” Journal of Clinical Oncology, vol. 26, supplement 20, abstract 6006, 2008. View at Google Scholar
  22. M. Merlano, E. Russi, M. Benasso et al., “Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study,” Annals of Oncology, vol. 22, no. 3, pp. 712–717, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. K. K. Ang, Q. E. Zhang, D. I. Rosenthal et al., “A randomized phase III trial (RTOG, 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC),” Journal of Clinical Oncology, vol. 29, abstract 5500, 2011. View at Google Scholar
  24. J. Baselga, D. Pfister, M. R. Cooper et al., “Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin,” Journal of Clinical Oncology, vol. 18, no. 4, pp. 904–914, 2000. View at Google Scholar · View at Scopus
  25. J. B. Vermorken, J. Trigo, R. Hitt et al., “Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2171–2177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Baselga, J. M. Trigo, J. Bourhis et al., “Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5568–5577, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. R. S. Herbst, M. Arquette, D. M. Shin et al., “Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5578–5587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere, “Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group Study,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8646–8654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Bourhis, F. Rivera, R. Mesia et al., “Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 24, no. 18, pp. 2866–2872, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. J. B. Vermorken, R. Mesia, F. Rivera et al., “Platinum-based chemotherapy plus cetuximab in head and neck cancer,” The New England Journal of Medicine, vol. 359, no. 11, pp. 1116–1127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Crombet, M. Osorio, T. Cruz et al., “Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1646–1654, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Rojo, E. Gracias, N. Villena et al., “Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study,” Clinical Cancer Research, vol. 16, no. 8, pp. 2474–2482, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. O. Rodríguez, T. C. Rivero, R. D. C. Bahi et al., “Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck,” Cancer Biology and Therapy, vol. 9, no. 5, pp. 343–349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. K. G. Babu, L. Viswanath, B. K. Reddy et al., “An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study,” Journal of Clinical Oncology, vol. 28, abstract 5530, p. 15s, 2010. View at Google Scholar
  35. L. J. Wirth, A. M. Allen, M. R. Posner et al., “Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck,” Annals of Oncology, vol. 21, no. 2, pp. 342–347, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Gupta and V. Madholia, “Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck,” vol. 28, no. 15s, abstract 5565, 2010. View at Google Scholar
  37. J. B. Vermorken, J. Stohlmacher, F. Cognetti et al., “Primary Efficacy and Safety Results of SPECTRUM, a Phase III Trial in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M-SCCHN) Receiving Chemotherapy With or Without Panitumumab,” in Proceedings of the 35th ESMO Congress, Milan, Italy, October 2010.
  38. J. P. Machiels, S. Subramanian, A. Ruzsa et al., “Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: An open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 4, pp. 333–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Guo, G. Ren, C. Li et al., “Pilot study of target therapy with EGFR antibody (nimotuzumab) in patients with unresectable head and neck cancer,” Journal of Clinical Oncology, vol. 29, abstract e16008, 2011. View at Google Scholar
  40. N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, and J. Mendelsohn, “Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model,” Clinical Cancer Research, vol. 1, no. 11, pp. 1311–1318, 1995. View at Google Scholar · View at Scopus
  41. J. D. Sato, T. Kawamoto, A. D. Le, J. Mendelsohn, J. Polikoff, and G. H. Sato, “Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors,” Molecular Biology & Medicine, vol. 1, no. 5, pp. 511–529, 1983. View at Google Scholar · View at Scopus
  42. G. N. Gill, T. Kawamoto, and C. Cochet, “Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity,” Journal of Biological Chemistry, vol. 259, no. 12, pp. 7755–7760, 1984. View at Google Scholar · View at Scopus
  43. Z. Fan, Y. Lu, X. Wu, and J. Mendelsohn, “Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells,” Journal of Biological Chemistry, vol. 269, no. 44, pp. 27595–27602, 1994. View at Google Scholar · View at Scopus
  44. M. Naramura, S. D. Gillies, J. Mendelsohn, R. A. Reisfeld, and B. M. Mueller, “Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma,” Cancer Immunology Immunotherapy, vol. 37, no. 5, pp. 343–349, 1993. View at Publisher · View at Google Scholar · View at Scopus
  45. H. Kimura, K. Sakai, T. Arao, T. Shimoyama, T. Tamura, and K. Nishio, “Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor,” Cancer Science, vol. 98, no. 8, pp. 1275–1280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Kurai, H. Chikumi, K. Hashimoto et al., “Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines,” Clinical Cancer Research, vol. 13, no. 5, pp. 1552–1561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Masui, T. Kawamoto, and J. D. Sato, “Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies,” Cancer Research, vol. 44, no. 3, pp. 1002–1007, 1984. View at Google Scholar · View at Scopus
  48. Z. Fan, J. Baselga, H. Masui, and J. Mendelsohn, “Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts,” Cancer Research, vol. 53, no. 18, pp. 4637–4642, 1993. View at Google Scholar · View at Scopus
  49. S. M. Huang, J. M. Bock, and P. M. Harari, “Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck,” Cancer Research, vol. 59, no. 8, pp. 1935–1940, 1999. View at Google Scholar · View at Scopus
  50. S. M. Huang and P. M. Harari, “Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis,” Clinical Cancer Research, vol. 6, no. 6, pp. 2166–2174, 2000. View at Google Scholar · View at Scopus
  51. L. Milas, K. Mason, N. Hunter et al., “In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody,” Clinical Cancer Research, vol. 6, no. 2, pp. 701–708, 2000. View at Google Scholar · View at Scopus
  52. L. Milas, F. M. Fang, K. A. Mason et al., “Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 2, pp. 568–572, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Zhang, K. Erjala, J. Kulmala et al., “Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro,” Radiotherapy and Oncology, vol. 92, no. 3, pp. 388–392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. C. R. Divgi, S. Welt, M. Kris et al., “Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma,” Journal of the National Cancer Institute, vol. 83, no. 2, pp. 97–104, 1991. View at Google Scholar · View at Scopus
  55. R. Perez-Soler, N. J. Donato, D. M. Shin et al., “Tumor epidermal growth factor receptor studies in patients with non- small-cell lung cancer or head and neck cancer treated with monoclonal antibody RG 83852,” Journal of Clinical Oncology, vol. 12, no. 4, pp. 730–739, 1994. View at Google Scholar · View at Scopus
  56. H. Modjtahedi, T. Hickish, M. Nicolson et al., “Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer,” British Journal of Cancer, vol. 73, no. 2, pp. 228–235, 1996. View at Google Scholar · View at Scopus
  57. F. Robert, M. P. Ezekiel, S. A. Spencer et al., “Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer,” Journal of Clinical Oncology, vol. 19, no. 13, pp. 3234–3243, 2001. View at Google Scholar · View at Scopus
  58. D. M. Shin, N. J. Donato, R. Perez-Soler et al., “Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer,” Clinical Cancer Research, vol. 7, no. 5, pp. 1204–1213, 2001. View at Google Scholar · View at Scopus
  59. J. J. Caudell, S. M. Sawrie, S. A. Spencer et al., “Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 3, pp. 676–681, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Koutcher, E. Sherman, and M. Fury, “Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer,” International Journal of Radiation Oncology, Biology and Physics, vol. 81, no. 4, pp. 915–922, 2011. View at Google Scholar
  61. J. Lefebvre, Y. Pointreau, F. Rolland et al., “Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study,” Journal of Clinical Oncology, vol. 29, supplement, abstract 5501, 2011. View at Google Scholar
  62. R. Hitt, A. Irigoyen, H. Cortes-Funes et al., “Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck,” Annals of Oncology, vol. 23, no. 4, pp. 1016–1022, 2011. View at Google Scholar
  63. J. Buentzel, A. de Vries, and O. Micke, “Experience with Cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer,” Journal of Clinical Oncology, vol. 25, no. 18s, 2007, ASCO Annual Meetings Proceedings Part I. View at Google Scholar
  64. M. K. Knoedler, T. Gauler, A. Matzdorff et al., “Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN,” Journal of Clinical Oncology, vol. 27, abstract 6048, p. 15s, 2009. View at Google Scholar
  65. J. Guigay, J. Fayette, A. Dillies et al., “Cetuximab, Docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): first results of phase II trial GORTEC, 2008-03,” Journal of Clinical Oncology, vol. 29, abstract 5567, 2011. View at Google Scholar
  66. A. Argiris, A. P. Kotsakis, S. Kim et al., “Phase II trial of Cetuximab (C) and Bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): final results,” Journal of Clinical Oncology, vol. 29, abstract 5564, 2011. View at Google Scholar
  67. B. Tschechne, I. Wildfang, H. Niebuhr et al., “Bendamustine and Cetuximab as an alternative therapeutic option for recurrent head and neck squamous cell carcinoma,” Journal of Clinical Oncology, vol. 28, supplement, abstract e16029, 2010. View at Google Scholar
  68. I. R. Correia, “Stability of IgG isotypes in serum,” MAbs, vol. 2, no. 3, pp. 221–232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. B. B. Yang, P. Lum, A. Chen et al., “Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab,” Clinical Pharmacokinetics, vol. 49, no. 11, pp. 729–740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Schneider-Merck, J. J. Van Lammerts Bueren, S. Berger et al., “Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage,” Journal of Immunology, vol. 184, no. 1, pp. 512–520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Stoehlmacher-Williams, C. Villanueva, P. Foa et al., “Safety and efficacy of panitumumab in HPV positive and HPV negative recurrent/metastatic SCC of HN: analysis of the phase III SPECTRUM trial,” in Proceedings of the European Multidisciplinary Cancer Congress, 2011.
  72. M. B. Overdijk, S. Verploegen, J. H. van den Brakel et al., “Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition,” The Journal of Immunology, vol. 187, no. 6, pp. 3383–3390, 2011. View at Google Scholar
  73. C. Mateo, E. Moreno, K. Amour, J. Lombardero, W. Harris, and R. Pérez, “Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity,” Immunotechnology, vol. 3, no. 1, pp. 71–81, 1997. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Crombet, L. Torres, E. Neninger et al., “Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer,” Journal of Immunotherapy, vol. 26, no. 2, pp. 139–148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Basavaraj, P. Sierra, J. Shivu, R. Melarkode, E. Montero, and P. Nair, “Nimotuzumab with chemoradiation confers survival advantage in treatment naïve head and neck tumors overexpressing EGFR,” Cancer Biology and Therapy, vol. 10, no. 7, pp. 673–681, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Bier, T. Hoffmann, U. Hauser et al., “Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx,” Cancer Chemotherapy and Pharmacology, vol. 47, no. 6, pp. 519–524, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. U. Vanhoefer, M. Tewes, F. Rojo et al., “Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 175–184, 2004. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Clynes, “Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity,” Hematology/Oncology Clinics of North America, vol. 20, no. 3, pp. 585–612, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Krapp, Y. Mimura, R. Jefferis, R. Huber, and P. Sondermann, “Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity,” Journal of Molecular Biology, vol. 325, no. 5, pp. 979–989, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. R. Jefferis, “Glycosylation as a strategy to improve antibody-based therapeutics,” Nature Reviews Drug Discovery, vol. 8, no. 3, pp. 226–234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Patel, X. Guo, S. Ng et al., “IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab,” Human Antibodies, vol. 19, no. 4, pp. 89–99, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. L. G. Paz-Ares, C. Gomez-Roca, J. P. Delord et al., “Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors,” Journal of Clinical Oncology, vol. 29, no. 28, pp. 3783–3790, 2011. View at Google Scholar
  83. M. Schlaeth, S. Berger, S. Derer et al., “Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells,” Cancer Science, vol. 101, no. 5, pp. 1080–1088, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. R. T. Curnow, “Clinical experience with CD64-directed immunotherapy. An overview,” Cancer Immunology Immunotherapy, vol. 45, no. 3-4, pp. 210–215, 1997. View at Publisher · View at Google Scholar · View at Scopus
  85. A. B. Van Spriel, H. H. Van Ojik, and J. G. J. Van de Winkel, “Immunotherapeutic perspective for bispecific antibodies,” Immunology Today, vol. 21, no. 8, pp. 391–397, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. M. G. Fury, A. Lipton, K. M. Smith, C. B. Winston, and D. G. Pfister, “A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors,” Cancer Immunology, Immunotherapy, vol. 57, no. 2, pp. 155–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Repp, C. Kellner, A. Muskulus et al., “Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC,” Journal of Immunological Methods, vol. 373, pp. 167–278, 2011. View at Google Scholar
  88. P. A. Ascierto, E. Simeone, M. Sznol, Y. X. Fu, and I. Melero, “Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies,” Seminars in Oncology, vol. 37, no. 5, pp. 508–516, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Pander, M. Heusinkveld, T. van der Straaten et al., “Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab,” Clinical Cancer Research, vol. 17, no. 17, pp. 5668–5673, 2011. View at Google Scholar
  90. J. Stagg, S. Loi, U. Divisekera et al., “Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 17, pp. 7142–7147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Google Scholar
  92. J. Dong, A. Sereno, D. Aivazian et al., “A stable IgG-Like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity,” MAbs, vol. 3, no. 3, pp. 273–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. H. Zhang, S. Yun, and T. D. Batuwangala, “A dual-targeting antibody against EGFR-VEGF for lung and head and neck cancer treatment,” International Journal of Cancer, vol. 131, no. 4, pp. 956–969, 2012. View at Google Scholar
  94. S. J. Hurwitz, H. Zhang, S. Yun et al., “Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 3, pp. 577–590, 2012. View at Google Scholar
  95. G. Schaefer, L. Haber, L. M. Crocker et al., “A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies,” Cancer Cell, vol. 20, no. 4, pp. 472–486, 2011. View at Google Scholar
  96. M. J. Mattes and D. M. Goldenberg, “Therapy of human carcinoma xenografts with antibodies to EGFr and HER-2 conjugated to radionuclides emitting low-energy electrons,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 7, pp. 1249–1258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. B. Pfost, C. Seidl, M. Autenrieth et al., “Intravesical α-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice,” Journal of Nuclear Medicine, vol. 50, no. 10, pp. 1700–1708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Rades, C. Wolff, R. Nadrowitz et al., “Radioactive EGFR antibody cetuximab in multimodal cancer treatment: stability and synergistic effects with radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 75, no. 4, pp. 1226–1231, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. Z. Liu, Y. Liu, B. Jia et al., “Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using90Y-labeled fully human antibody panitumumab,” Molecular Cancer Therapeutics, vol. 9, no. 8, pp. 2297–2308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Casaco, G. López, R. Fernandez et al., “Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188-Re,” Journal of Clinical Oncology, vol. 22, no. 14S, abstract 2530, 2004, ASCO Annual Meeting Proceedings (Post-Meeting Edition). View at Google Scholar
  101. S. R. Schwartz, B. Yueh, J. K. McDougall, J. R. Daling, and S. M. Schwartz, “Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study,” Otolaryngology, vol. 125, no. 1, pp. 1–9, 2001. View at Publisher · View at Google Scholar · View at Scopus